U.S. Markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
515.56-28.54 (-5.25%)
At close: 4:00PM EST

514.50 -1.06 (-0.21%)
After hours: 4:25PM EST

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
914 847 7000

Full Time Employees8,314

Key Executives

NameTitlePayExercisedYear Born
Dr. Leonard S. SchleiferCo-Founder, Pres, CEO & Exec. Director4.77M111.22M1953
Dr. George D. YancopoulosCo-Founder, Pres & Chief Scientific Officer & Director3.98M87.3M1960
Mr. Robert E. Landry Jr.Exec. VP of Fin. & CFO1.56MN/A1964
Dr. Andrew J. MurphyExec. VP of Research1.29M7.93M1958
Mr. Daniel P. Van PlewExec. VP and GM of Industrial Operations & Product Supply1.46MN/A1973
Ms. Patrice GiloolySr. VP of Quality Assurance & OperationsN/AN/AN/A
Mr. Christopher R. FenimoreSr. VP, Head of Accounting & ControllerN/AN/A1971
Mr. Gerald UnderwoodSr. VP of Technical OperationsN/AN/AN/A
Mr. Bob McCowanSr. VP of IT & Chief Information OfficerN/AN/AN/A
Justin HolkoVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.